atrasentan has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holmes, DR; Kent, B; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E | 1 |
| Lennon, R; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E; Reriani, M; Rihal, C | 1 |
2 trial(s) available for atrasentan and Coronary Artery Disease
| Article | Year |
|---|---|
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Topics: Adult; Antihypertensive Agents; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Edema; Endothelin A Receptor Antagonists; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension; Kidney; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrrolidines; Receptor, Endothelin A; Risk Factors; Treatment Outcome | 2008 |
Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.
Topics: Adult; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Coronary Circulation; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Rate; Humans; Kidney; Lipoprotein(a); Male; Microcirculation; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrrolidines; Receptor, Endothelin A; Triglycerides; Uric Acid | 2010 |